Salmonellosis is a significant global health concern caused by the Gram-negative bacterium Salmonella. Through innovative research, rigorous preclinical testing, and strategic collaborations, our company is committed to providing specialized salmonellosis vaccine and therapeutic development solutions.
Overview of Salmonellosis
Salmonellosis is an infectious disease caused by the Salmonella bacteria, a group of rod-shaped, Gram-negative bacilli within the Enterobacteriaceae family. This disease is predominantly characterized by gastrointestinal symptoms, including diarrhea, fever, and abdominal cramps, typically manifesting 6 hours to 6 days after exposure to the pathogen.
Two primary forms of Salmonellosis exist: typhoidal and non-typhoidal. Typhoidal Salmonella, particularly Salmonella enterica serovar Typhi, is responsible for typhoid fever, a systemic infection that can lead to severe complications if untreated. In contrast, non-typhoidal Salmonella (NTS) encompasses various serotypes that primarily cause gastroenteritis.
Fig.1 S. Typhimurium uses its virulence factors for ecosystem engineering. (Rogers A. W., et al., 2021)
Vaccine Development for Salmonellosis
The development of vaccines against salmonellosis has been a focal point for researchers and the biopharmaceutical industry. Several strategies have been employed to create effective vaccines:
Live Attenuated Vaccines
Live attenuated vaccines, such as the Ty21a for Salmonella Typhi, have demonstrated efficacy in enteric fever. These vaccines provide a robust immune response by mimicking natural infection, though their use has been limited to specific serovars.
Subunit and Conjugate Vaccines
Subunit vaccines, which incorporate purified bacterial components like O-antigens and flagellin proteins, have shown promise in preclinical studies. Conjugate vaccines, linking these antigens to carrier proteins, enhance immunogenicity and are being explored for broader protection against various Salmonella serovars.
Generalized modules for membrane antigens (GMMA) represent an innovative approach, presenting surface polysaccharides and outer membrane proteins in their native conformation. This self-adjuvating technology has the potential to offer high immunologic potency at a low cost, which is particularly beneficial for global health.
Therapeutics Development for Salmonellosis
| Therapeutics |
Description |
| Antibiotic Therapy |
Traditionally, antibiotics, such as ciprofloxacin, ceftriaxone, and ampicillin, have been the cornerstone of salmonellosis therapeutics. However, the emergence of antibiotic-resistant strains has necessitated the search for alternative therapies. |
| Probiotics and Prebiotics |
Probiotics, such as Saccharomyces boulardii, have demonstrated the ability to modulate the host immune response and exert antagonistic effects against Salmonella. Prebiotics can enhance the growth of beneficial bacteria, indirectly combating Salmonella colonization. |
| Bacteriophage Therapy |
Bacteriophages, which are viruses that target bacteria, have garnered interest due to their precise targeting and effectiveness in combating antibiotic resistance. They have the unique ability to specifically attack harmful bacteria while leaving the good ones unharmed. |
Our Services
At our company, we are dedicated to advancing the development of vaccines and therapeutic strategies for salmonellosis. Our multidisciplinary team combines expertise in microbiology, immunology, and preclinical research to provide comprehensive development services.
Preclinical Research
- Drug Safety Evaluation
- In Vivo Pharmacokinetics Study
- In Vitro Pharmacokinetics Study
- Activity Testing
- Drug Resistance Evaluation
Disease Models
- Humanized Mouse Models: Salmonella Typhi
- Rabbit Models: peroral and intraperitoneal infection
- Streptomycin-Treated Mouse Models
- Ileal Loop Models: calves, rabbits, pigs, and primates
- Zebrafish Embryos
Our research initiatives focus on identifying novel vaccine candidates through extensive in vitro and in vivo studies. We leverage cutting-edge technologies, including genomic and proteomic analyses, to discover potential antigens that can be utilized in the formulation of effective vaccines. Our comprehensive services are designed to meet these challenges head-on, propelling the field forward in the quest to mitigate the impact of these devastating diseases. If you are interested in our services, please feel free to contact us.
References
- Rogers, Andrew WL, Renée M. Tsolis, and Andreas J. Bäumler. "Salmonella versus the Microbiome." Microbiology and Molecular Biology Reviews 85.1 (2021): 10-1128.
- Gut, Abraham Majak, et al. "Salmonella infection–prevention and treatment by antibiotics and probiotic yeasts: a review." Microbiology 164.11 (2018): 1327-1344.
- Higginson, Ellen E., Raphael Simon, and Sharon M. Tennant. "Animal models for salmonellosis: applications in vaccine research." Clinical and Vaccine Immunology 23.9 (2016): 746-756.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
